• FR |

Del Nery Elaine

Responsable PlateformeMise à jour le 24/11/2016

Brevets / Publications / Communications

Horvath P, Aulner N, Bickle M, Davies AM, E Del Nery, Ebner D, Montoya MC, Östling P, Pietiäinen V, Price LS, Shorte SL, Turcatti G, von Schantz C, Carragher NO. Screening out irrelevant cell-based models of disease. Nat Rev Drug Discov. 2016 Sep 12.

Functional assessment of genetic variants with outcomes adapted to clinical decision-making P Thouvenot, B Ben Yamin, L Fourrière, A Lescure,T Boudier, E Del Nery, A.Chauchereau, D Goldgar, C Houdayer, D Stoppa-Lyonnet, ANicolas, Gaël A. Millot. PLOS Genetics 2016, 12 (6).

A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1. Canal F, Anthony E, Lescure A, Del Nery E, Camonis J, Perez F, Ragazzon B, Perret C. BMC Cancer. 2015 Dec 29;15(1):1020.

 High content screening in chemical biology: overview and main challenges. Brodin , Del Nery E., Soleilhac. Med Sci (Paris). 2015 Feb;31(2):187-96.

Mahmood SF, Gruel N, Chapeaublanc E, Lescure A, Jones T, Reyal F, Vincent-Salomon A, Raynal V, Pierron G, Perez F, Camonis J, Del Nery E, Delattre O, Radvanyi F, Bernard-Pierrot I. A siRNA screen identifies RAD21, EIF3H, CHRAC1 and TANC2 as driver genes within the 8q23, 8q24.3 and 17q23 amplicons in breast cancer with effects on cell growth, survival and transformation. Carcinogenesis. 2014, 35(3):670-82.

Schauer K, Grossier JP, Duong T, Chapuis V, Degot S, Lescure A, Del Nery E, Goud B. A Novel Organelle Map Framework for High-Content Cell Morphology Analysis in High Throughput J Biomol Screen. 2014 19(2):317-24.